Search - tctmd.com

Displaying 1 - 10 of 10

Sort: Relevancy | Date

‘Acceptable Safety’ for LAA Closure Seen in a Real-World, All-Comers Registry

News Conference News AHA 2017

‘Acceptable Safety’ for LAA Closure Seen in a Real-World, All-Comers Registry

November 22, 2017

Complications Spiked, Then Fell, After Initial Introduction of Watchman LAA Closure Device

News Daily News

Complications Spiked, Then Fell, After Initial Introduction of Watchman LAA Closure Device

October 12, 2017

Atrial Fibrillation in Obese Patients a Growing Concern, Experts Say

News Daily News

Atrial Fibrillation in Obese Patients a Growing Concern, Experts Say

October 10, 2017

No Anticoagulation Benefit, High Bleeding Risk Seen in Patients With Secondary A-fib

News Daily News

No Anticoagulation Benefit, High Bleeding Risk Seen in Patients With Secondary A-fib

Michael O'Riordan

September 29, 2017

ESC Releases Revamped DAPT Guidance Focusing on Personalized Approach

News Conference News ESC 2017

ESC Releases Revamped DAPT Guidance Focusing on Personalized Approach

September 01, 2017

Add-on LAA Occlusion in Cardiac Surgery Cuts Thromboembolism Risk in A-fib Patients

News Conference News ACC 2017

Add-on LAA Occlusion in Cardiac Surgery Cuts Thromboembolism Risk in A-fib Patients

March 21, 2017

Timing and Dose Matters When It Comes to Statin Therapy Before CABG Surgery

News Daily News

Timing and Dose Matters When It Comes to Statin Therapy Before CABG Surgery

Michael O'Riordan

March 16, 2017

Fish Oils: Yes for HF and Secondary Prevention, No for the General Population, Says AHA

News Daily News

Fish Oils: Yes for HF and Secondary Prevention, No for the General Population, Says AHA

Michael O'Riordan

March 15, 2017

NOACs Seem to Perform Just Fine in Patients With A-fib and Most Types of Valvular Disease

News Daily News

NOACs Seem to Perform Just Fine in Patients With A-fib and Most Types of Valvular Disease

March 14, 2017

ACC 2017: CVD Outcomes for Evolocumab, Intermediate-Risk TAVR, Coronary Physiology Tests, and More

News Conference News ACC 2017

ACC 2017: CVD Outcomes for Evolocumab, Intermediate-Risk TAVR, Coronary Physiology Tests, and More

March 10, 2017

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.